Hepatotoxicity and Hepatic Dysfunction



After initial evaluation of a cancer patient, the building of a treatment plan is an important step. In the setting of multiple therapeutic modalities, chemotherapy is the most widely used one. The metabolism and clearance of chemotherapy drugs are mostly dependent on normally functioning kidney and liver.

Especially, the liver is the keystone for the metabolism (i.e., inactivation or activation) and clearance of anticancer agents which are commonly used in different types of cancers. Assessment of liver function and uncovering of preexisting liver diseases should be the approach before starting and also during therapy.


Bilirubin Level Hepatic Dysfunction Dose Modification Serum Bilirubin Level Adefovir Dipivoxil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Swick RW, Barnstein PL, Stange JL. The metabolism of mitochondrial proteins. I. Distributrion adn characterization of the isozymes of alanine aminotransferase in rat liver. J Biol Chem 1965; 240:3334–3341.PubMedGoogle Scholar
  2. 2.
    Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172:367–379.PubMedGoogle Scholar
  3. 3.
    Gholson CF, Morgan K, Catinis G et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997; 92:1788–1792.PubMedGoogle Scholar
  4. 4.
    Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37:1286–1292.PubMedCrossRefGoogle Scholar
  5. 5.
    Low JK, Hojin K, Hoskins PJ et al. Fatal reactivation of hepatitis B post chemotherapy for lymphoma in a hepatitis B surface antigen negative hepatitis B core antibody positive patient. Leuk Lymphoma 2005; 46:1085–1089.CrossRefGoogle Scholar
  6. 6.
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925.PubMedGoogle Scholar
  7. 7.
    Kawatani T, Suou T, Tajima F et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67:45.PubMedCrossRefGoogle Scholar
  8. 8.
    Wai CT, Tan BH, Chan CL et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27:465.PubMedCrossRefGoogle Scholar
  9. 9.
    Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008; 24:287.PubMedCrossRefGoogle Scholar
  10. 10.
    Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731.PubMedCrossRefGoogle Scholar
  11. 11.
    Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 2005; 129:512.PubMedGoogle Scholar
  12. 12.
    De Pree C, Giastro E, Galatto A et al. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesaphageal carcinoma. Ann Oncology 1994; 5:861–862.Google Scholar
  13. 13.
    Santini D, Picardi A, Vincenci B et al. Severe liver dysfunction after ralitrexed administration in a HCV positive colorectal cancer patient. Cancer Invest 2003; 21:162–163.PubMedCrossRefGoogle Scholar
  14. 14.
    Salt WB II. Nonalcoholic fatty liver disease (NAFLD) a comprehensive review. J Insur Med 2004; 36:27–41.PubMedGoogle Scholar
  15. 15.
    Zeiss J, Merrick HW, Savolaine ER, Woldenberg LS, Kim K, Schlembach PJ. Fatty liver change as a result of hepatic artery infusion chemotherapy. Am J Clin Oncol 1990; 13:156–160.PubMedCrossRefGoogle Scholar
  16. 16.
    Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey J-N, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274–286.PubMedCrossRefGoogle Scholar
  17. 17.
    Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43:618.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.PubMedCrossRefGoogle Scholar
  19. 19.
    Snyder LS, Heigh RI, Anderson ML. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener’s granulomatosis. Mayo Clin Proc 1993; 68:1203.PubMedCrossRefGoogle Scholar
  20. 20.
    Shaunak S, Munro JM, Weinbren K et al. Cyclophosphamide induced liver necrosis: a possible interaction with azathioprine. Q J Med, New Series 1988;252:309–317.Google Scholar
  21. 21.
    King PD, Perry MC. Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Source Book, Third Edition, Perry, MC (ed), Lippincott, Williams and Wilkins, Philadelphia, 2001. p. 487.Google Scholar
  22. 22.
    Paschke R, Worst P, Brust J, Queisser W. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie 1988; 11:273.PubMedCrossRefGoogle Scholar
  23. 23.
    Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12:37–44.PubMedGoogle Scholar
  24. 24.
    Amromin GD, Delman RM, Shanbran E. Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 1962; 42:401–410.PubMedGoogle Scholar
  25. 25.
    Koler, RD, Forsgren, AL. Hepatotoxicity due to chlorambucil; report of a case. J Am Med Assoc 1958; 167:316.PubMedCrossRefGoogle Scholar
  26. 26.
    Peters WP, Henner WD, Grochow LB et al. Clinical and pharmacological effects of high-dose single-agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987; 47:6402–6406.PubMedGoogle Scholar
  27. 27.
    Koren G, Beatty K, Seto A et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992; 26:363.PubMedGoogle Scholar
  28. 28.
    Pizzuto J, Aviles A, Ramos E et al. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol 1983; 11:287.PubMedCrossRefGoogle Scholar
  29. 29.
    George CB, Mansour RP, Redmond J 3rd, Gandara DR. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 1984; 54:2360.PubMedCrossRefGoogle Scholar
  30. 30.
    Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70:1059.PubMedGoogle Scholar
  31. 31.
    Bateman JR, Pugh RP, Cassidy FR et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971; 28:907.PubMedCrossRefGoogle Scholar
  32. 32.
    Hohn D, Melnick J, Stagg R et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3:98.PubMedGoogle Scholar
  33. 33.
    Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274–286.PubMedCrossRefGoogle Scholar
  34. 34.
    Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interaction between capecitabine and warfarin: a case report and review of the literature. Int J Clin Pharmacol Ther 2006; 44(2):80–82.PubMedGoogle Scholar
  35. 35.
    Aki Z, Kotiloğlu G, Ozyilkan O. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. Am J Gastroenterol 2000; 95(4):1093–1094.PubMedGoogle Scholar
  36. 36.
    Robinson K, Lambiase L, Li J, Monteiro C, Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003; 48:1804–1808.PubMedCrossRefGoogle Scholar
  37. 37.
    Saif MW, Shahrokni A, Cornfeld D. Gemcitabine-induced liver fi brosis in a patient with pancreatic cancer. JOP 2007; 8:460–467.PubMedGoogle Scholar
  38. 38.
    McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1959; 14:80–90.PubMedGoogle Scholar
  39. 39.
    Romagnuolo J, Sadowski DC, Lalor E et al. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12:479.PubMedGoogle Scholar
  40. 40.
    Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann Intern Med 1976; 85:578.PubMedGoogle Scholar
  41. 41.
    Leme PR, Creaven PJ, Allen LM, Berman M. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep 1975; 59:811.PubMedGoogle Scholar
  42. 42.
    Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978; 23:68.PubMedGoogle Scholar
  43. 43.
    Farrell GC. Drug-Induced Liver Disease. Churchill Livingstone, New York, 1994.Google Scholar
  44. 44.
    Buroker TR, Kim PN, Baker LH et al. Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. Med Pediatr Oncol 1978; 4:35.PubMedCrossRefGoogle Scholar
  45. 45.
    Hirth J, Watkins PB, Strawderman M et al. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6:1255.PubMedGoogle Scholar
  46. 46.
    Mathijssen RH, van Alphen RJ, Verweij J et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182.PubMedGoogle Scholar
  47. 47.
    Ramanathan RK, Egorin MJ, Takimoto CH et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:563.PubMedCrossRefGoogle Scholar
  48. 48.
    Hirth J, Watkins PB, Strawderman M et al. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6:1255.PubMedGoogle Scholar
  49. 49.
    Alert letter available online at http://www.fda.gov/medwatch/safety/2008/tarceva_dhcp.letter.pdf, accessed September 24, 2008).
  50. 50.
    Kim YH, Mio T, Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis. Intern Med 2009; 48:1677.PubMedCrossRefGoogle Scholar
  51. 51.
    Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2:336.PubMedGoogle Scholar
  52. 52.
    Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81:297–306.PubMedCrossRefGoogle Scholar
  53. 53.
    Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64:281–291.PubMedCrossRefGoogle Scholar
  54. 54.
    Wanless IR, Godwin TA, Allen F et al. Nodular regenerative hyperplasia of the liver in hematological disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with a hypothesis on the pathogenesis. Medicine 1980; 59:367.PubMedCrossRefGoogle Scholar
  55. 55.
    Fleming DR, Wolff SN, Fay JW et al. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin’s disease: a phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 1999; 35:91.PubMedCrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Department of Medical OncologyBaskent University School of Medicine, Baskent Universitesi Adana Hastanesi Kisla Yerleskesi Tibbi Onkoloji BD Kazim Karabekir cadYuregirAdanaTurkey

Personalised recommendations